Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma


Based on encouragingin vitro andin vivo data, 14 consecutive patients with measurable metastatic previously untreated colorectal carcinoma were treated with a combination of intravenous etoposide and subcutaneous alpha-interferon. Etoposide was given at 60 mg/m2 intravenously on days 1–5 and alpha-interferon at 5 million units/m2 subcutaneously on days 1–5; courses were repeated every 21 days. All 14 patients were evaluable for response and toxicity. None of the patients achieved a complete or partial remission. Toxicity of this combination was moderate. Our data suggest that this combination is ineffective against colorectal carcinoma.

This is a preview of subscription content, log in to check access.


  1. 1.

    Boring CC, Squires TS, Tong T. Cancer Statistics, 1992. Ca 42:19–38, 1992

  2. 2.

    Poon MA, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Tschetter LK, Levitt R, Kardinal CG, Mailliard JA. Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9:1967–1972, 1992

  3. 3.

    Von Hoff DD.In vitro data supporting interferon plus cytotoxic agent combinations. 18:58–61, 1991

  4. 4.

    Krigel RL, Slywotzky CM, Lonberg M, Green MD, Andes WA, Kempf R, Gupta S, Grace W, Spiegel RJ, Muggia FM, Grossberg H. Treatment of epidemic Kaposi's sarcoma with a combination of interferon-alpha-2b and etoposide. J Biol Resp Modif 7:359–364, 1988

  5. 5.

    Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH. Comprehensive criteria for therapy-induced toxicity. Cancer Invest 8:141–153, 1990

Download references

Author information

Correspondence to Jaffer A. Ajani.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ajani, J.A., Abbruzzese, J.L., Markowitz, A.B. et al. Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma. Invest New Drugs 11, 67–69 (1993). https://doi.org/10.1007/BF00873914

Download citation

Key words

  • etoposide
  • alpha-interferon
  • colorectal carcinoma